前往化源商城
入驻化源商城

品牌现货直购
供应商:我要出现这里






查看所有供应商和价格请点击:

8047-67-4生产厂家

8047-67-4价格

8047-67-4

8047-67-4结构式
8047-67-4结构式
  • 常用中文名:蔗糖铁
  • 常用英文名:Iron sucrose
  • CAS号:8047-67-4
  • 分子式:C18H24Fe2O24
  • 分子量:736.059
  • 相关类别: 生物化工 糖类化合物 双糖
  • 发布时间:2018-09-30 18:21:25
  • 更新时间:2024-01-02 18:54:45
  • Iron sucrose (Iron saccharate) 是一种静脉注射铁制剂和一种促氧化剂。Iron sucrose 可用于缺铁性贫血的研究。

化源商城直购

中文名 蔗糖铁
英文名 Iron saccharate
英文别名 Venofer
ferrivenin
Sucrofer
EINECS 232-464-7
MFCD00166305
Fesin
Hippiron
Iron(3+) D-glucarate (2:3)
ironsugar
iviron
proferrin
feojectin
描述 Iron sucrose (Iron saccharate) 是一种静脉注射铁制剂和一种促氧化剂。Iron sucrose 可用于缺铁性贫血的研究。
相关类别
体外研究 静脉注射蔗糖铁可使血红蛋白、平均红细胞体积、血清铁、铁蛋白和铁饱和度百分比显著增加,总铁结合能力相应降低[1]。体外生存分析表明,10毫米抗坏血酸暴露(2小时)克隆灭活40-80%的指数生长结肠癌细胞系(HCT116和HT29)。当结肠癌细胞在存在或不存在250μM铁蔗糖的情况下进行处理,然后冲洗,并使用10 mM抗坏血酸进行处理时,与单用药理学抗坏血酸相比,这些细胞显示出不稳定铁的水平增加,从而显著增加克隆细胞的杀伤作用[2]。细胞内粘附分子-1(ICAM-1)和血管细胞粘附分子-1(VCAM-1)在蔗糖铁处理的人主动脉内皮细胞中通过上调NADPH氧化酶(NOx)和NF-κB信号通路表达,增加U937细胞的粘附。在160μg/mL的浓度下,蔗糖铁显著地诱导细胞内ROS产生在1到3小时之间的时间依赖性增加,但在4小时时效果减弱[3]。
体内研究 蔗糖铁能显著增加肾大部切除小鼠组织超氧化物的产生、组织细胞粘附分子的表达和内皮细胞的粘附性。蔗糖铁可加重去势ApoE-/-小鼠主动脉的动脉粥样硬化[3]。
参考文献

[1]. Kristiyana Kaneva, et al. Intravenous Iron Sucrose for Children With Iron Deficiency Anemia. J Pediatr Hematol Oncol. 2017 Jul;39(5):e259-e262.

[2]. Kristin E Brandt, et al. Augmentation of Intracellular Iron Using Iron Sucrose Enhances the Toxicity of Pharmacological Ascorbate in Colon Cancer Cells. Redox Biol. 2018 Apr;14:82-87.

[3]. Ko-Lin Kuo, et al. Iron Sucrose Accelerates Early Atherogenesis by Increasing Superoxide Production and Upregulating Adhesion Molecules in CKD. J Am Soc Nephrol. 2014 Nov;25(11):2596-606.

[4]. Richard A Zager, et al. Combined Iron Sucrose and Protoporphyrin Treatment Protects Against Ischemic and Toxin-Mediated Acute Renal Failure. Kidney Int. 2016 Jul;90(1):67-76.

沸点 766.4ºC at 760 mmHg
熔点 MORE THAN 51ºC
分子式 C18H24Fe2O24
分子量 736.059
闪点 431.2ºC
精确质量 735.935608
PSA 483.54000
储存条件 室温,干燥

CHEMICAL IDENTIFICATION

RTECS NUMBER :
NO7700000
CHEMICAL NAME :
Iron oxide, saccharated
CAS REGISTRY NUMBER :
8047-67-4
LAST UPDATED :
199512

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
180 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,193,1982
TYPE OF TEST :
LDLo - Lowest published lethal dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rabbit
DOSE/DURATION :
150 mg(Fe)/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
BJPCAL British Journal of Pharmacology and Chemotherapy. (London, UK) V.1-33, 1946-68. For publisher information, see BJPCBM. Volume(issue)/page/year: 10,375,1955 ** TUMORIGENIC DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1560 mg/kg/13W-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Reproductive - Tumorigenic effects - other reproductive system tumors
REFERENCE :
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 60,708,1989
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
148 gm/kg/74W-I
TOXIC EFFECTS :
Tumorigenic - neoplastic by RTECS criteria Tumorigenic - tumors at site of application
REFERENCE :
BMJOAE British Medical Journal. (British Medical Assoc., BMA House, Tavistock Sq., London WC1H 9JR, UK) V.1- 1857- Volume(issue)/page/year: 1,947,1959
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
104 gm/kg/13W-I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Tumorigenic - tumors at site of application
REFERENCE :
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8. Volume(issue)/page/year: 24,109,1960
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
150 gm/kg/I
TOXIC EFFECTS :
Tumorigenic - equivocal tumorigenic agent by RTECS criteria Blood - lymphoma, including Hodgkin's disease Tumorigenic - tumors at site of application
REFERENCE :
BECCAN Annual Report--Cancer Research Campaign. (Cancer Research Campaign, 2 Carlton House Terrace, London SW1Y 5AR, UK) V.1- 1924- Volume(issue)/page/year: 40,30,1962 *** REVIEWS *** IARC Cancer Review:Animal Limited Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 2,161,1973 IARC Cancer Review:Human No Adequate Data IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 2,161,1973 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,56,1987 TOXICOLOGY REVIEW PEXTAR Progress in Experimental Tumor Research. (S. Karger AG, Postfach CH-4009 Basel, Switzerland) V.1- 1960- Volume(issue)/page/year: 12,102,1969

海关编码 3004909090
海关编码 3004909090